Radiation therapy for small kidney tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of kidney cancer (clear cell type or similar).
- Your tumor is 7 cm or smaller and has not spread to other parts of the body.
- You are not a candidate for surgery due to medical reasons or you choose not to have surgery.
- Your kidney function is good (eGFR is 30 or higher).
- You have not had radiation to the same area or systemic therapy for kidney cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a precise, high-dose radiation technique (called stereotactic body radiation therapy) that tracks and treats kidney tumors while you breathe. It aims to destroy tumors without surgery, potentially offering a less invasive option for people who cannot or prefer not to have an operation.
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests a precise type of radiation called stereotactic body proton therapy for people with kidney cancer who cannot have surgery or other local treatments. It aims to see if this focused radiation can control the tumor with fewer side effects.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
This trial tests a combination of precise radiation (SBRT) plus two drugs (anlotinib and bimepolizumab) to see if it helps control advanced kidney cancer. The goal is to shrink tumors and slow the cancer's growth.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.